On March 20, GLONGHUI | Yuanda Pharmaceutical (00512.HK) announced that for the year ended December 31, 2023, the Group's business grew steadily, with revenue of about HK$10.53 billion, an increase of about 10.1% over the previous year. Excluding the effects of changes in the exchange rate between RMB and HKD, this is an increase of about 15.8% compared to the same period in 2022. During the period under review, profit attributable to company owners was approximately HK$1.88 billion, a year-on-year decrease of approximately 9.6%. The current period's normalized profit attributable to company owners was approximately RMB 2,036 million, down about 4.7% from the same period last year. Excluding the effects of changes in the exchange rate between RMB and HKD, this is an increase of about 0.2% compared to the same period in 2022. The Group recorded a gross margin of about 62.0% during the period, compared to about 62.2% for the same period in 2022.
Based on the Group's good performance, with the goal of promoting all shareholders to share the company's operating and development results and effectively protecting shareholders' interests, this year the board of directors proposed paying a final dividend of HK26 cents per share for the year 2023, totaling approximately HK$905 million. As of December 31, 2023, the Group continued to invest resources in the promotion of ongoing research projects and the introduction of innovative projects. In addition to R&D expenses, capitalized R&D expenses, advance payments for new projects and other investments, the Group invested approximately HK$1,441 billion in R&D work and projects.